$ABT

Stratton John G purchased $174K of ABT

Stratton John G purchased 2,000 shares of ABBOTT LABORATORIES (ABT) at $86.82 ($0.17M total) on 2026-05-07.

Original reporting
SEC EDGAR · Stratton John G
Published Jun 18, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ABT
Bullish
medium confidence
Mentioned
$ABT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABTBullishLow
01

Why it matters

A director’s open-market purchase adds a small positive sentiment datapoint but does not introduce new operational, financial, or regulatory information.

02

Market read

Traders may note insider buying, but the lack of fundamental catalysts suggests limited trading edge.

03

What to watch

No 10b5-1 plan and the filing date lags the trade date; the market may already have priced any sentiment effect.

Relevance 5/10Novelty 5/10Timing: new Form 4 filed 2026-06-18 (covers 2026-05-07 purchase)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Abbott Laboratories.

Company-level read

Ticker impact

$ABTBullishMedium confidence
Context

Abbott Laboratories director Stratton John G filed a Form 4 open-market purchase of 2,000 shares at $86.82 on 2026-05-07.

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

Form 4 provides a fresh datapoint (insider buying), yet the transaction size and lack of accompanying corporate news reduce tradable signal strength.

Market effects

Minimal; single-insider transaction without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (e.g., diversification or compensation-related) and may not reflect a strong forward view.

Key entities

  • Abbott Laboratories

    Issuer of the Form 4; insider purchase disclosed.

  • Stratton John G

    Director who purchased 2,000 ABT shares at $86.82.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABTLow

Whistleblowers Help DOJ Achieve $385 Million Settlement with Abbott Laboratories for Contaminated Infant Formula Sold to Government Programs – RACmonitor

Abbott Laboratories agreed to a $385M settlement with the DOJ for alleged false claims related to contaminated infant formula sold to government programs. The settlement resolves claims that Abbott failed to meet manufacturing standards at its Michigan and Arizona facilities. The company did not admit liability. The settlement includes $348.7M to the federal government and $36.3M to state Medicaid programs. Three whistleblowers will receive $69M for their role in exposing the allegations.

$ABTLow

Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything

Abbott Laboratories agreed to a $385M settlement to resolve a False Claims Act lawsuit over alleged contamination at its Sturgis, Michigan, and Casa Grande, Arizona, plants. The DOJ and state AGs filed the suit, citing poor conditions and alleged concealment of contamination tests. Abbott denied liability. The 2022 recall caused widespread formula shortages. Whistleblowers will receive $69M.

MedAI 8/10

Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative?

Abbott Laboratories received FDA approval for upgrades to its CardioMEMS HF System and launched SimpleScreen CRC, a blood-based colorectal cancer screening test. These updates extend Abbott's reach in heart failure monitoring and early cancer detection. Analysts expect 8.8% yearly revenue growth and profit margins rising to 16.0% by 2029, with a consensus earnings forecast of $9.6b by 2029.